Chronic Kidney Disease (CKD) Management Guidelines

KDIGO Clinical Practice Guideline Summary

Stage Classification:
- Stage 3b: eGFR 30-44 mL/min/1.73m²
- Stage 4: eGFR 15-29 mL/min/1.73m²
- Stage 5: eGFR <15 mL/min/1.73m²

Key Management Principles:

1. Blood Pressure Control
   - Target BP <130/80 mmHg for most CKD patients
   - ACE inhibitors or ARBs preferred for patients with albuminuria
   - Monitor potassium and creatinine after initiation

2. Diabetes Management
   - HbA1c target <7% for most patients
   - Metformin: Use caution if eGFR 30-45, avoid if <30
   - SGLT2 inhibitors (empagliflozin, dapagliflozin) show renoprotective benefits

3. Anemia Management
   - Target Hgb 10-11.5 g/dL
   - Consider ESAs and iron supplementation
   - Workup: iron studies, B12, folate

4. Mineral and Bone Disorder
   - Monitor calcium, phosphorus, PTH, vitamin D
   - Phosphate binders if hyperphosphatemia
   - Active vitamin D analogs for secondary hyperparathyroidism

5. Metabolic Acidosis
   - Treat if serum bicarbonate <22 mEq/L
   - Sodium bicarbonate supplementation
   - May slow CKD progression

6. Medication Safety
   - Avoid NSAIDs
   - Adjust doses for renal function
   - Contrast precautions for imaging

7. Nephrology Referral
   - eGFR <30 (Stage 4)
   - Rapid decline in kidney function
   - Difficult to manage complications
   - Consider dialysis planning

8. Cardiovascular Risk Reduction
   - Statin therapy for ASCVD risk reduction
   - Monitor and treat hypertension aggressively
   - Lifestyle modifications

References: KDIGO 2024, NKF 2023

